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A 53-year-old woman with persistent breast
cancer after autologous bone marrow transplant
7 years previously for breast cancer was admitted
to an outside institution because of
gastrointestinal bleeding. Because of clinical
symptoms related to anemia secondary to the
gastrointestinal blood loss, a request for RBC
transfusion was made. Routine serologic
evaluation of the patient’s blood sample
demonstrated the presence of anti-c, and the
patient was transfused with c–, crossmatch-
compatible RBCs. As a result of ongoing
transfusion requirements, the patient was
transferred to our institution, at which time her
plasma contained anti-c and anti-Jkb. The patient
was transfused with 4 units of c–, Jk(b–), RBCs
that were crossmatch compatible by PEG (PeG,
Gamma Biologicals, Inc., Houston, TX)-IAT
(Gamma-clone Anti-IgG, Immucor/Gamma,
Houston, TX) and sustained an appropriate rise
in her hematocrit. The patient was discharged to
home 48 hours after transfusion. Five days later
she was readmitted with fever and recurrent
anemia; a delayed hemolytic transfusion reaction
(HTR) was suspected. Pertinent blood bank
findings included the presence of anti-c
(previously identified), anti-Jkb (previously
identified), and anti-s (new) (Table 1, Reaction 1).
The patient’s RBCs were positive by the DAT with
anti-IgG (2+) (Gamma-clone Anti-IgG, Immucor/
Gamma) and negative with anti-C3 (Gamma-
clone Anti-C3b,C3d, Immucor/Gamma). Eluate
analysis (Gamma ELU-KIT II, Gamma Biologicals,
Inc.) demonstrated anti-s and anti-Jkb. Because of
ongoing hemolysis, the patient’s Hct declined to
22%. A unit of RBCs was requested to manage
symptomatic anemia. Owing to the complex
antibody picture, specimens were referred to an
immunohematology reference laboratory (IRL)
to evaluate for additional antibody specificities.
Testing revealed the presence of anti-c, anti-Jkb,
anti-s, probable anti-N, and probable HTLA
(specificity undetermined); the presence of anti-
K and anti-Fyb could not be excluded. The DAT
was negative using the most recent RBC sample.
RBCs selected to lack c, K, s, Fyb, Jkb, and N were
found to be weakly crossmatch incompatible at
the antiglobulin (AHG) phase by the LISS tube
method (ImmuAdd, Immucor/Gamma). The
patient was transfused with 1 unit of RBCs
without incident. However 2 hours after the
transfusion, she developed a 2°F rise in
temperature, chills, rigors, and dark urine.
This patient clearly manifested the hallmarks of an
acute HTR, on the heels of a delayed HTR. HTRs are a
consequence of RBC destruction and can be caused by
an antibody-mediated process or a non–antibody-
mediated process. The pathophysiology of the former
is described here; the latter will be briefly reviewed
later. Antibody-mediated acute HTRs occur when
transfused RBCs bearing a foreign antigen are attacked
by recipient antibodies directed against that antigen.
ABO-incompatible transfusions are notorious for
mediating acute HTRs, largely owing to the fact that the
responsible antibodies are naturally occurring, or
non–RBC stimulated (i.e., immune stimulation from a
previous RBC transfusion is not required); are of the
IgM class (which ably fixes complement); and are
present in high titer. Non-ABO antibodies have been
associated with acute HTRs, but in general these
reactions are less severe (Table 2). The complex
sequence of events after IgM antibody–associated
complement activation is driven by the proteolytic
cleavage of complement proteins. Through this
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activation process a host of biologic mediators are
generated; in addition, the complement activation
cascade promotes assembly of the pore-like membrane
attack complex (C5b-9). Formation of the membrane
attack complex on the surface of the RBC instigates
intravascular lysis (Fig. 1).1 The reticuloendothelial
system also contributes to RBC destruction via
erythrophagocytosis of complement (C3b)-coated
RBCs.2 In contrast, IgG-mediated antibody RBC
destruction is thought to be largely extravascular. The
fate of RBCs in this instance can take one of three
paths, all presumably mediated by Fcγ receptors of
splenic macrophages: (1) endocytotic removal of the
sensitized RBC, (2) spherocyte formation as a result of
membrane ingestion by the splenic macrophages, or
(3) antibody-dependent cell-mediated cytolysis (ADCC;
Fig. 2).3
The clinical manifestations observed in HTRs are
secondary to cytokine generation after complement
activation as well as cellular interaction between
antibody- or complement-coated RBCs and phagocytic
cells. Most notable are fever (attributable to increased
production and release of interleukin 1 [IL-1], IL-6, IL-8,
and tumor necrosis factor α) and pain at the
intravenous site (likely related to complement proteins
C3a and C3b).4 Other less frequent symptoms include
dyspnea, hypotension, nausea, and flushing.5 Newly
developed animal models of alloimmunization hold
promise for further elucidation of the specific
pathways involved in antibody-mediated RBC
destruction and their physiologic consequences.6,7 In a
murine model using transgenic mice expressing human
glycophorin A, Schirmer et al.6 have examined the
kinetics of IgM- and IgG-mediated removal of
incompatible RBCs. Their results mirror previously
reported chromium survival studies of antibody-
mediated removal of RBCs performed in humans, thus
supporting the model’s potential to dissect the
complexities of HTRs.8 The investigators, using this
model,hope to more clearly define the role of antibody
class (IgM versus IgG) and IgG subclasses, complement
proteins, and cellular Fcγ receptors in the
pathophysiology of HTRs.6
Table 1. Summary of transfusion reaction investigations
Transfusion Reaction 1 Transfusion Reaction 2 Transfusion Reaction 3
Before After Before After Before After
Visual inspection of plasma Yellow Amber Yellow Amber Yellow Orange
Serum antibodies anti-c, anti-Jkb anti-c, anti-Jkb, anti-c, anti-Jkb, anti-c, anti-Jkb, anti-c, anti-Jkb, anti-c, anti-Jkb,
anti-s anti-s, probable anti-s, HTLA anti-s anti-s*
anti-N, HTLA
DAT Neg IgG-2+, C3-neg Neg IgG- microscopically Neg
positive, C3-neg
Eluate anti-s, anti-Jkb anti-s, anti-Jkb Neg
Hematocrit (%) 32 25 22 22 23 22
LDH (IU/L) 230 1,278 831 1,109 694 1,447
Haptoglobin (mg/dL) 101 <20 <20 <20 <20 <20
Indirect bilirubin (mg/dL) 0.1 3.9 0.2 0.9 0.2 3.1
BUN (mg/dL) 13 20 14 24 20 27
Creatinine (mg/dL) 0.7 0.8 0.7 0.9 1.7 1.6
*Anti-Doa was identified by an immunohematology reference laboratory 1 week after the transfusion reaction event.
BUN = blood urea nitrogen
Fig. 1. Complement-mediated intravascular destruction of RBCs.
Fig. 2. IgG antibody-mediated extravascular destruction of RBCs.
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In response to the patient’s clinical symptoms
of fever, chills and rigors, and hematuria after
transfusion of the most recent RBC component, a
transfusion reaction investigation was requested.
A posttransfusion specimen and the requisition
for transfusion reaction investigation were
submitted. During the 2-hour interval between
completion of the RBC transfusion and the
patient’s onset of symptoms, the blood
component bag had been discarded into the
hazardous waste container on the nursing unit,
and therefore was unavailable to the blood bank
laboratory for evaluation. On receipt of the post-
transfusion specimen, the tube was centrifuged;
examination of the plasma showed visual
evidence of hemolysis (Table 1, Reaction 2).
Repeat ABO typing (Gamma-clone, Immucor/
Gamma) was performed and group A was
confirmed. A DAT was performed, which demon-
strated a microscopic positive reaction with anti-
IgG (Gamma-clone Anti-IgG, Immucor/Gamma);
no C3 was demonstrable using anti-C3 (Gamma-
clone Anti-C3b,C3d, Immucor/Gamma) (with
appropriate controls). An eluate analysis (Gamma
ELU-KIT II, Gamma Biologicals, Inc.) demonstrated
the presence of anti-s and anti-Jkb.
In cases in which there is clinical concern for an
HTR, a methodical approach to the laboratory
evaluation is critical. The recent AABB publication
Guidelines for the Laboratory Evaluation of Transfusion
Reactions provides a useful resource for the evaluation
of an HTR.9 The authors describe a tiered approach to
transfusion reaction investigation. The first tier
includes a clerical check and three tests on a post-
transfusion specimen: (1) visual check for evidence of
plasma hemoglobinemia (Fig. 3), (2) repeat ABO typing
[NB: Repeat ABO typing was not included in the
Guidelines as the AABB Standards for Blood Banks and
Transfusion Services,22nd edition,added this testing to
the first tier of investigation after publication of the
guidelines in 2003.10], and (3) DAT. The clerical check
is one of the most important steps for the exclusion of
an ABO mistransfusion event as the cause of an HTR. It
reviews for any errors in component labeling, including
patient name and identifier (e.g., hospital record
number), ABO group, and compatibility tags. In
addition, the clerical check should include
confirmation of the request for transfusion as well as
prior transfusion history, transfusion restrictions, and
the results of pretransfusion testing. After completion
of the clerical check,a visual check for hemolysis in the
posttransfusion specimen should be performed and,
immediately afterward, an ABO determination. A
discrepant ABO group in the posttransfusion specimen
(when compared with the patient’s historic type)
raises the concern for an ABO-incompatible
transfusion. In these instances, all units reserved for
the patient in question should be quarantined, a
request for another specimen for ABO typing should be
made, and the blood bank medical director notified. If
the transfusion reaction investigation reveals a positive
DAT in the posttransfusion specimen, a DAT should be
performed on a pretransfusion specimen to assess for
an interval change. An antibody-mediated acute
hemolytic transfusion event should be considered if an
interval change is observed (i.e., pretransfusion DAT is
negative and posttransfusion DAT is positive), and the
Fig. 3. Visual check for hemolysis. This image depicts the interval
change in plasma color after a hemolytic transfusion reaction.
The plasma from the pretransfusion specimen (Tube A) is yellow
and clear. The plasma in the immediate posttransfusion specimen
(Tube B) is red, consistent with the presence of free hemoglobin.
Tube C depicts the interval color change secondary to
metabolism of hemoglobin occurring during subsequent days
after a hemolytic transfusion event.










laboratory should immediately take additional steps to
clarify. As in the case in which an ABO transfusion
error is suspected on the basis of a posttransfusion
ABO type discrepancy, an interval change in the DAT
should prompt the laboratory to quarantine reserved
units and notify the blood bank medical director.
Although a majority of individuals experiencing an
acute HTR will have a positive DAT,5 a negative DAT
does not exclude the possibility of an immune-based
HTR, particularly when there is evidence of plasma
hemoglobinemia. This is most likely to occur in the
setting of ABO-incompatible transfusion reactions, in
which sensitized RBCs are rapidly removed from the
circulation or hemolyzed.11 In some settings in which
the DAT is negative, further investigation via an RBC
eluate analysis (considered to be third-tier testing) may
provide clues to the cause of the HTR.
As noted previously, a positive (or discrepant) test
result on a posttransfusion specimen is concerning and
requires additional laboratory investigation. Suggested
tests include repeat antibody screen, repeat crossmatch
(carried through to the AHG phase of testing), repeat
antigen typing of units in cases in which antigen-
negative units were selected for transfusion, and
evaluation of the RBC component for evidence of
hemolysis (preferably the returned bag, otherwise unit
segments are recommended).9 The repeat antibody
screen and crossmatch should be performed initially
using the methods routinely used by the laboratory. If
repeat testing is not illuminating, then use of more
sensitive methods is recommended (e.g., PEG additive,
enzymes, extended incubation). More sophisticated
methods (third-tier testing) can be used in cases in
which first- and second-tier testing is unrevealing as to
the cause of the apparent immune HTR. Generally,
these investigations are performed by IRLs and include
adsorption-elution studies and enhanced antibody
detection methods, including antibody neutralization
methods, antibody titration, and recipient and donor
antigen typing.9 Genotyping, a tool recently
introduced to the IRLs’ armamentarium, can be
particularly helpful in multiply transfused patients in
whom it may be difficult to separate patient RBCs from
transfused RBCs. In addition, genotyping may provide
information on antigens in which there are limited
antisera for typing available, for example, anti-Doa and
anti-Dob. In cases in which the hunt for an
unrecognized antibody is unrevealing, ancillary testing
for other causes of hemolysis should be considered.
These include flow cytometric analysis for CD59 to
rule out paroxysmal nocturnal hemoglobinuria,
evaluation for a Donath-Landsteiner antibody to rule
out underlying paroxysmal cold hemoglobinuria,12 and
consideration of drug-induced immune hemolytic
anemia.13
Other Considerations
When the laboratory transfusion investigation fails
to uncover an immune cause for a clearly apparent
HTR, it is important to exclude nonimmune causes of
hemolysis.12 One should exclude the possibility of
osmotic RBC lysis secondary to use of an incompatible
solution during transfusion (e.g., anything other than
normal saline risks consequent hemolysis) or improper
deglycerolization of a previously frozen unit. Exposure
of an RBC component to temperature extremes (less
than 0°C or greater than 40°C) may result in RBC lysis.
Should concern for an HTR occur coincident with a
surgical procedure or other therapeutic intervention in
which blood is being passed through an extracorporeal
circuit (e.g., hemodialysis or apheresis), mechanical
injury to RBCs should be excluded as a cause of the
apparent hemolytic event.
The transfusion medicine service was
consulted regarding patient management after
the episode of hemolysis, at which time they
recommended gentle hydration and sympto-
matic treatment of fever with acetaminophen.
Posttransfusion laboratory data (Table 1,
Reaction 2) were remarkable for a Hct of 22%
(unchanged from pretransfusion assessment),
LDH of 1,109 U/dL (increased from pre-
transfusion assessment), haptoglobin of < 20
mg/dL (unchanged), and indirect bilirubin of 0.9
mg/dL (increased from 0.2 mg/dL). Analysis of a
posttransfusion urine specimen was remarkable
for dark (black) color, large concentration of
blood by dipstick, and absent RBCs by micro-
scopy. However, the patient’s renal function
variables were not significantly different from
pretransfusion values (blood urea nitrogen: 14
mg/dL [pre], 24 mg/dL [post]; creatinine: 0.7
mg/dL [pre], 0.9 mg/dL [post]).
As illustrated by this case, assessment of hemolytic
variables may be helpful in the diagnosis and
determination of the magnitude of clinical impact of a
presumed HTR. These include urinalysis, looking for
evidence of hemoglobinuria (indicative of renal
clearance of free hemoglobin derived from hemolyzed
RBCs); increased LDH, an enzyme released into the
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intravascular compartment after the destruction of
RBCs (either intravascular or extravascular); indirect
hyperbilirubinemia; and decreased haptoglobin as a
consequence of increased clearance of heme-
haptoglobin complexes.14 Changes in these variables
of hemolysis are generally evident within hours of the
hemolytic event and normalize within days after
completion of the RBC destruction process (Fig. 4).15
For the patient suspected of having experienced an
HTR, treatment strategies are empiric; because the
potential magnitude of harm correlates with the
volume of RBCs transfused, discontinuation of RBC
transfusion is of paramount importance. Renal failure
is one of the more serious risks of immune hemolysis.
Consequently, treatment of hypotension with
crystalloids is important to maintain renal function.
Intravenous furosemide (20–80 mg) has been
advocated to maintain renal tubular flow in
hemodynamically stable patients.16 The role of
dopamine in low doses (“renal-dose”dopamine, 1–3 µg
• kg–1 • min–1), which promotes renal vasodilation
and increases urine output, to reduce the risk of anuric
renal failure in the setting of HTRs is unclear, and, in
general, it is not recommended.17 Alkalinization of the
urine with intravenous sodium bicarbonate (to a urine
pH of >6.5) makes hemoglobin more soluble, and may
prevent tubular obstruction by hemoglobin casts.18
Massive release of intracellular RBC stores of potassium
may produce critical hyperkalemia; thus, serum
potassium concentrations should be monitored closely.
Dialysis may be required in the setting of renal
impairment to manage severe hyperkalemia. Rarely,
disseminated intravascular coagulation (DIC) may
occur in the setting of acute immune hemolysis as a
result of procoagulant release during RBC destruction;
this consumptive process may, in addition,be fueled by
concomitant cytokine release. Similar to management
of renal impairment, the treatment of DIC is supportive
and based on the manifested abnormalities (e.g.,
transfusion of platelets for thrombocytopenia;
cryoprecipitated AHF for hypofibrinogenemia, FFP for
clotting factor deficiencies as assessed by prolongation
of prothrombin time and activated partial thrombo-
plastin time); heparin treatment is rarely necessary.
The patient remained stable after her second
transfusion reaction. No additional transfusions
were requested, and the patient was discharged
to home with a Hct of 23.2%. With respect to the
posttransfusion reaction serologic evaluation
(Reaction 2), specimens referred to an IRL failed
to demonstrate any additional clinically
significant alloantibodies. The patient was
advised to donate autologous blood components.
With the support of erythropoietin therapy, she
successfully donated four RBC units in the 6
months after the hemolytic transfusion event.
Future transfusion therapy should be based on the
findings of the laboratory transfusion reaction
investigation. In cases in which alloantibodies are
identified, it is appropriate to select antigen-negative
units that are crossmatched by an IAT. Autologous
donation is a consideration for those patients for whom
a transfusion reaction investigation demonstrates an
antibody to a high-prevalence antigen, or, as in this
case, transfusion therapy has been complicated by
alloimmunization and recurrent transfusion reactions
after transfusion with allogeneic blood. In such cases,
patient referral to a regional donor center may be
warranted so that units can be readily shipped in the
event of an urgent need for RBC transfusion outside of
the patient’s locale.
The patient presented to the hospital on
multiple occasions for management of anemia
related to persistent gastrointestinal bleeding
and bone marrow suppression secondary to
ongoing palliative chemotherapy. Blood trans-
fusion requirements were met using the patient’s
autologous units, all of which were transfused
uneventfully. Because of progression of the
Fig. 4. Time course of change in laboratory variables of hemolysis after
an acute hemolytic transfusion reaction. This graph depicts the
temporal change in LDH (LD; ), total bilirubin (Tbil; ),
haptoglobin (), and hematocrit (Hct; ) of a D+ patient with
idiopathic thrombocytopenic purpura who experienced an acute
hemolytic reaction after administration of Rh0(D) immune
globulin intravenous (WinRho SDF, Cangene Corporation,
Winnipeg,Manitoba,Canada). Within hours of report of an acute
hemolytic transfusion reaction, the patient’s serum LDH and
bilirubin rose, and haptoglobin dropped to undetectable levels.
Not unexpectedly, there was a concomitant decline in the
patient’s hematocrit.
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patient’s disease, she was unable to continue
autologous RBC donation, so when she was
readmitted with symptomatic anemia after
surgical stabilization of a pathologic fracture, a
request was made for allogeneic blood trans-
fusion. Once again, the serologic evaluation
demonstrated anti-c, anti-Jkb, and anti-s. Further
evaluation by an IRL confirmed the presence of
the alloantibodies, and recommendations were
made to transfuse with antigen-compatible, least-
incompatible RBCs. The patient received a single
unit of RBCs lacking E, c, Cw, K, Jkb, s, and Fya that
was weakly incompatible by PEG (PeG, Gamma
Biologicals, Inc.)-IAT but compatible by LISS
(ImmuAdd, Immucor/Gamma)-IAT. The patient
once again evidenced clinical symptoms of an
HTR (fever, chills and rigors, and hematuria)
after completion of the RBC transfusion (Table 1,
Reaction 3). A transfusion reaction investigation
was unrevealing, and specimens were referred to
a second IRL for additional evaluation. This
investigation led to the identification of anti-Doa.
The patient was subsequently successfully
transfused with an RBC unit lacking Doa, as well
as E, c, K, Jkb, and s.
The eventual identification of the anti-Doa is not
surprising.19 This antibody is difficult to identify. It is
often found in patients with multiple antibodies. It is
weakly reactive, requiring enhancement methods such
as PEG or testing with enzyme (ficin or papain)-treated
RBCs. And finding reagent RBCs typed for Dombrock
system antigens is difficult because of the rarity of
potent, reagent-grade typing sera.
Closing Comments
Significant advances promoting overall transfusion
safety, largely directed at the blood component itself,
have been made during the last three decades. Most
notable is the reduced risk of transfusion-transmitted
viral infection.20 Currently, the risk for transfusion-
associated hepatitis C virus and HIV viral transmission
is on the order of 1 in 2 million transfused units.21
Nevertheless, blood transfusion is not risk-free. Non-
infectious complications of transfusion, in particular
hemolytic transfusion reactions, continue to be among
the leading causes of transfusion-associated fatalities
(Fig. 5).22 Analysis of these events reproducibly shows
that a majority of acute HTRs are a consequence of
misidentification or incomplete identification of the
transfusion recipient, at either the time of
pretransfusion specimen acquisition or the time of
blood component transfusion.23 A much smaller
proportion of HTRs, like the one described in this
report, are caused by a failure to identify clinically
significant alloantibodies. These observations have
catalyzed the growing support for widespread
adoption of hemovigilance programs within the United
States. Such programs afford a mechanism by which
robust data on transfusion complications and errors
can be gathered and analyzed and, eventually,
contribute to the development of innovative
approaches to enhanced transfusion safety.24,25
Although hemovigilance programs will improve
transfusion safety, the challenge of detecting and
identifying antibodies given current methods and the
need for expertise in solving these types of problems
remains.
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